TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9104689

Group type: EXPERIMENTAL
Intervention: Late night partial sleep deprivation (LSD)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Early night partial sleep deprivation (ESD)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Recovery sleep after ESD (ESD-R)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Recovery sleep after LSD (LSD-R)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline late luteal phase
Number of subjects: 41
Study: 8253222

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops (2%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3515925

Group type: EXPERIMENTAL
Intervention: 50 mg of oral flurbiprofen
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 10 mg of intramuscular morphine sulfate
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 30714095

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomization schemes
Number of subjects: 3

Group type: COMPARATOR
Intervention: Naïve z-test
Number of subjects: 3
Study: 29446699

Group type: EXPERIMENTAL
Intervention: d-cycloserine (250 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 26615713

Group type: EXPERIMENTAL
Intervention: Thin split-thickness skin grafts (STSGs)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Occlusive hydrocellular dressing (Control Group B)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Paraffin gauze (Control Group C)
Number of subjects: 192
Study: 25851453

Group type: EXPERIMENTAL
Intervention: Urea, arginine and carnosine cream (UC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glycerin-based emollient cream (SEC)
Number of subjects: 50
Study: 23865124

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 70
Study: 21091788

Group type: EXPERIMENTAL
Intervention: C‐UCA (0%, 0.02%, 0.2%, or 2%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0% C‐UCA (placebo)
Number of subjects: 40
Study: 19146155

Group type: EXPERIMENTAL
Intervention: Dingweiban manipulation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Xieban manipulation
Number of subjects: 122
Study: 16602365

Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resilient telescopic crowns
Number of subjects: 25
Study: 14686724

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte (PEG-EL)
Number of subjects: 111
Study: 11074227

Group type: EXPERIMENTAL
Intervention: Citalopram (20‐60 mg/day)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Sertraline (50‐150 mg/day)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 8823568

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (3 mg/100 ml) and 5-aminosalicylic acid (2 g/100 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (3 mg/100 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (2 g/100 ml)
Number of subjects: 60
Study: 1316078

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally once daily for 14 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily for 14 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 63
Study: 31254631

Group type: EXPERIMENTAL
Intervention: Safe sleep counseling during well child visits (WCVs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal report of infant sleeping with a person or an object in sleep space
Number of subjects: 0
Study: 28161208

Group type: EXPERIMENTAL
Intervention: Laboratory Microscope (LM)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Home Microscope (HM)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Home Tablet (HT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 26227101

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (400/500/100 μg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: FF/VI (400/100 μg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: UMEC/VI (500/100 μg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: UMEC/VI (250/100 μg)
Number of subjects: 88
Study: 25610872

Group type: EXPERIMENTAL
Intervention: Intravaginal 1 mg prostaglandin E2
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intracervical 0.5 mg prostaglandin E2
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 21629206

Group type: EXPERIMENTAL
Intervention: MSH/ACTH(4-10)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19485284

Group type: EXPERIMENTAL
Intervention: Non-chopping rotation and axial rotation techniques
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Axial rotation technique
Number of subjects: 654

Group type: COMPARATOR
Intervention: Quick chop technique
Number of subjects: 654
Study: 17655633

Group type: EXPERIMENTAL
Intervention: Lignocaine gel
Number of subjects: 62

Group type: COMPARATOR
Intervention: Water-based lubricating gel
Number of subjects: 62
Study: 15954909

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily for 2 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily for 2 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg daily for 2 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 12141378

Group type: EXPERIMENTAL
Intervention: Hypertensive group (HT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normotensive group (NT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 10738352

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 1829
Study: 7763028

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics monitored dose adaptation of MTX (group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: T10 protocol with dose adapted only to age (group 1)
Number of subjects: 71
Study: 2325029

Group type: EXPERIMENTAL
Intervention: Uterine lavage with 2 g of cefotaxime in 1,000 mL of normal saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous administration of 1 g of cefotaxime after cord clamping followed by 1-g doses 6 and 12 hours later
Number of subjects: 100
Study: 527268

Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant cyclic chemotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Post-operative local radiation therapy
Number of subjects: 65
Study: 31830632

Group type: EXPERIMENTAL
Intervention: Algorithm-based artifact reduction algorithm (AAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iterative reconstruction technique 2 (IR2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iterative reconstruction technique 1 (IR1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAR
Number of subjects: 0
Study: 31348920

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block with methylenum coeruleum guided by ultrasound
Number of subjects: 87
Study: 29239024

Group type: EXPERIMENTAL
Intervention: On-pump bypass surgery
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Off-pump bypass surgery
Number of subjects: 2203
Study: 25554072

Group type: EXPERIMENTAL
Intervention: Dietary counseling to increase fish intake
Number of subjects: 18
Study: 22178145

Group type: EXPERIMENTAL
Intervention: Educational intervention (Powerpoint presentation)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 232
Study: 21296519

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mifepristone (internal standard)
Number of subjects: 0
Study: 19336724

Group type: EXPERIMENTAL
Intervention: 12.5% DL-alpha-tocopherol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17088141

Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal spray (200 microg, once daily for 28 days)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 15593225

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study: 11488165

Group type: EXPERIMENTAL
Intervention: LeukoNorm Cytochemia administered on 5 consecutive days starting with the day of oocyte retrieval (1 unit/10 kg dosage)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal treatment group (non-treatment group)
Number of subjects: 10
Study: 9251876

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 8431907

Group type: EXPERIMENTAL
Intervention: Pelvic radiation treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pelvic lymph node dissection
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Groin irradiation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Surgical dissection
Number of subjects: 114
Study: 3119677

Group type: EXPERIMENTAL
Intervention: BW 942C (0.5 mg intravenous)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 28293779

Group type: EXPERIMENTAL
Intervention: Minodronate (50 mg/28 days)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 µg/day)
Number of subjects: 121
Study: 26639352

Group type: EXPERIMENTAL
Intervention: Eplerenone (100 mg/dose, 2 doses, 24h between doses)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24556825

Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE inhibitor)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23332478

Group type: EXPERIMENTAL
Intervention: Fully branded female packs
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Packs without descriptor words
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Packs without brand imagery or descriptors (plain packs)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Branded non-female brands
Number of subjects: 947
Study: 20883060

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (TM) group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 57
Study: 18418363

Group type: EXPERIMENTAL
Intervention: Paroxetine (12.5-75 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-375 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison of paroxetine and venlafaxine
Number of subjects: 86
Study: 16028343

Group type: EXPERIMENTAL
Intervention: EPS-guided/ICD strategy (n = 79)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional strategy (n = 59)
Number of subjects: 143
Study: 12461273

Group type: EXPERIMENTAL
Intervention: 3‐T magnetic resonance (MR) spectroscopy
Number of subjects: 14
Study: 15539258

Group type: EXPERIMENTAL
Intervention: Pulp oil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Paraffin oil
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Seed oil
Number of subjects: 49
Study: 7861314

Group type: EXPERIMENTAL
Intervention: Flexible correction model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idiographic measures of theories of bias
Number of subjects: 0
Study: 1945967

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonmedicated skin cleanser
Number of subjects: 40
Study: 7037757

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 46
Study: 30010101

Group type: EXPERIMENTAL
Intervention: Neural therapy (6 sessions)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (stretching exercises only)
Number of subjects: 102
Study: 26353843

Group type: EXPERIMENTAL
Intervention: Grazoprevir 25 mg plus PEG‐IFN/RBV
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Grazoprevir 50 mg plus PEG‐IFN/RBV
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg plus PEG‐IFN/RBV
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study: 24433574

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (TT) patch delivering 300 mcg of testosterone/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo patch (Pl)
Number of subjects: 44
Study: 21955035

Group type: EXPERIMENTAL
Intervention: Maternal glycohemoglobin A(1) concentration in the 2nd trimester was 9.2% for offspring born with asymmetric LGA.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Maternal glycohemoglobin A(1) concentration in the 2nd trimester was 7.5% for those born with symmetric LGA or AGA.
Number of subjects: 19
Study: 20726624

Group type: EXPERIMENTAL
Intervention: Patient reminders
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: One-on-one interactions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Eliminating structural barriers
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: System-level changes
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Educational small-media interventions
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Decision aids
Number of subjects: 116

Group type: COMPARATOR
Intervention: No interventions tested
Number of subjects: 116
Study: 17920738

Group type: EXPERIMENTAL
Intervention: Aligned shell brace
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aligned sleeve brace
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-braced condition
Number of subjects: 10
Study: 16190388

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) 1.2 x 10(4) U/kg intravenously after induction, 0.6 x 10(4) U/kg UTI in priming solution, and 0.6 x 10(4) U/kg UTI 5 min before aortic decamping
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 24
Study: 12074692

Group type: EXPERIMENTAL
Intervention: Lanoteplase 120 kU/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Alteplase 100 mg (bolus) + two-stage 90 min infusion
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lanoteplase
Number of subjects: 31

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 31
Study: 10787398

Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg/day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 8863926

Group type: EXPERIMENTAL
Intervention: Grass-pollen allergen extract Alutard SQ
Number of subjects: 30

Group type: COMPARATOR
Intervention: Histamine (placebo)
Number of subjects: 30
Study: 1734364

Group type: EXPERIMENTAL
Intervention: Gentamicin otic drops immediately after tympanostomy tube placement in the operating room only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin otic drops for an additional 48 hours (4 drops in each ear, three times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 6372437

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate 15 mg/kg twice daily for ten days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate 25 mg/kg twice daily for ten days
Number of subjects: 102
Study: 30207000

Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong (ZZKZ) capsule
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 28846002

Group type: EXPERIMENTAL
Intervention: Parenting daily hassles and parental depressive symptoms
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Household chaos (parent report)
Number of subjects: 402
Study: 26215770

Group type: EXPERIMENTAL
Intervention: True acupressure
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo acupressure (sham acupressure)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 108
Study: 23494526

Group type: EXPERIMENTAL
Intervention: Booster treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 118
Study: 22539783

Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: non-HDL cholesterol
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: apolipoprotein B
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: LDL particle number
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: HDL particle number
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: total HDL particle number
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: small HDL particle number
Number of subjects: 20000
Study: 20150438

Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for HER2
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for estrogen receptor (ER)
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for progesterone receptor (PgR)
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for p53
Number of subjects: 2123
Study: 18842455

Group type: EXPERIMENTAL
Intervention: Patient-held QoL diary (EORTC-QLQ-C30 and LC13 in A5 format)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of diary completion
Number of subjects: 57
Study: 15917540

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fasting and fed states
Number of subjects: 8
Study: 12872741

Group type: COMPARATOR
Intervention: Randomly sampled residents
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Patients from dental clinics
Number of subjects: 1140
Study: 10570376

Group type: EXPERIMENTAL
Intervention: Conventional UVA1 phototherapy (50 J/cm²/day for 15 days)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: UVA1 cold-light phototherapy (50 J/cm²/day for 15 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Combined UVA-UVB phototherapy (minimal erythema dose dependent for 15 days)
Number of subjects: 120
Study: 8553408

Group type: EXPERIMENTAL
Intervention: Lubeluzole 10 mg/d
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Lubeluzole 20 mg/d
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 1846437

Group type: EXPERIMENTAL
Intervention: Unopposed conjugated equine estrogen (0.625 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate, norethindrone acetate, or d,l-norgestrel (doses providing protection against endometrial hyperplasia)
Number of subjects: 3
Study: 6478427

Group type: EXPERIMENTAL
Intervention: Involved field (IF) radiotherapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: Extended field (EF) radiotherapy
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Chemotherapy after initial radiotherapy
Number of subjects: 460
Study: 31712590

Group type: EXPERIMENTAL
Intervention: Drinking two 150 ml glasses of water (Study 1 and Study 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Not drinking water (Study 1 and Study 2)
Number of subjects: 68
Study: 29953439

Group type: EXPERIMENTAL
Intervention: Pegbovigrastim
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (physiologic saline)
Number of subjects: 34
Study: 27110900

Group type: EXPERIMENTAL
Intervention: 5 minutes of mindful breathing (MB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal listening
Number of subjects: 60
Study: 24277961

Group type: EXPERIMENTAL
Intervention: Intranasal clonidine 4 mcg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal midazolam 0.3 mg/kg
Number of subjects: 60
Study: 23302459

Group type: EXPERIMENTAL
Intervention: MRS-guided stereotactic biopsy
Number of subjects: 126

Group type: COMPARATOR
Intervention: MRI-guided stereotactic biopsy
Number of subjects: 126
Study: 20219285

Group type: EXPERIMENTAL
Intervention: Cross-sex hormonal treatment in MF transsexuals
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cross-sex hormonal treatment in FM transsexuals
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control males
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control females
Number of subjects: 18
Study: 17532158

Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17369712

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg BW/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg BW/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg BW/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg BW/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 0.7 g/kg BW/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: >=0.8 g/kg BW/day
Number of subjects: 121
Study: 15487439

Group type: EXPERIMENTAL
Intervention: Stressful sound stimuli (noise)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No noise
Number of subjects: 17
Study: 11420762

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 125
Study: 9445630

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New cytotoxic agents (gemcitabine, vinorelbine, topotecan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with paclitaxel and docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective aromatase inhibitors, new antigestagens, and antiestrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose intensity concepts with growth factors and peripheral stem cell support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Humanized monoclonal antibody against CerbB‐2 receptors
Number of subjects: 0